{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/EXEL/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T11:59:14.199Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8827,"canonical_name":"EXELIXIS, INC.","cik":"0000939767","uei":null,"lei":null,"duns":null,"ticker":"EXEL"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":25,"clinical":2,"lobbying":1},"count":28,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"8-K","title":"8-K — EXELIXIS, INC. — 2026-09-11","url_slug":"/sec/cik-0000939767/8-k/0000939767-26-000108","accession_number":"0000939767-26-000108","importance":35},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Eckhardt Sue Gail","title":"Director","shares":9812,"usd_value":499136,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001969223-26-000611","importance":40.099827288},{"ts":"2026-06-01","kind":"sec.form144","reporter":"JACK L WYSZOMIERSKI","title":"Director","shares":3925,"usd_value":198409,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001950047-26-005335","importance":40.03968175},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Eckhardt Sue Gail","title":null,"shares":9812,"price_per_share":50.14,"usd_value":491974,"security_title":"Common Stock","importance":35.49197368},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"WYSZOMIERSKI JACK L","title":null,"shares":3925,"price_per_share":50.55,"usd_value":198409,"security_title":"Common Stock","importance":35.19840875},{"ts":"2026-06-01","kind":"sec.filing","form_type":"144","title":"144 — WYSZOMIERSKI JACK L — 2026-06-01","url_slug":"/sec/cik-0001023225/144/0001950047-26-005335","accession_number":"0001950047-26-005335","importance":30},{"ts":"2026-05-20","kind":"sec.form144","reporter":"PATRICK JOSEPH HALEY","title":"Officer","shares":32110,"usd_value":1599444,"security_title":"Common","approx_sale_date":"2026-05-20","accession_number":"0001950047-26-004829","importance":40.31988881},{"ts":"2026-05-18","kind":"sec.form144","reporter":"CHRISTOPHER J SENNER","title":"Officer","shares":34901,"usd_value":1745179,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001950047-26-004712","importance":40.349035826},{"ts":"2026-05-18","kind":"sec.form144","reporter":"BRENDA JOY HEFTI","title":"Officer","shares":6625,"usd_value":332641,"security_title":"Common","approx_sale_date":"2026-05-18","accession_number":"0001950047-26-004674","importance":40.06652825},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Senner Christopher J.","title":"EVP and CFO","shares":34901,"price_per_share":50,"usd_value":1745050,"security_title":"Common Stock","importance":36.74505},{"ts":"2026-05-18","kind":"sec.insider.s","reporter":"Hefti Brenda","title":"SVP and General Counsel","shares":6625,"price_per_share":50.21,"usd_value":332641,"security_title":"Common Stock","importance":35.33264125},{"ts":"2026-05-18","kind":"sec.insider.g","reporter":"MORRISSEY MICHAEL","title":"President and CEO","shares":124047,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-18","kind":"sec.insider.g","reporter":"MORRISSEY MICHAEL","title":"President and CEO","shares":124047,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"MORRISSEY MICHAEL","title":"President and CEO","shares":128497,"price_per_share":51.1,"usd_value":6566197,"security_title":"Common Stock","importance":21.5661967},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Senner Christopher J.","title":"EVP and CFO","shares":40892,"price_per_share":51.1,"usd_value":2089581,"security_title":"Common Stock","importance":17.0895812},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Haley Patrick J.","title":"EVP, Commercial","shares":33265,"price_per_share":51.1,"usd_value":1699842,"security_title":"Common Stock","importance":16.6998415},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Aftab Dana","title":"EVP, Research and Development","shares":30578,"price_per_share":51.1,"usd_value":1562536,"security_title":"Common Stock","importance":16.5625358},{"ts":"2026-05-15","kind":"sec.insider.f","reporter":"Hefti Brenda","title":"SVP and General Counsel","shares":6411,"price_per_share":51.1,"usd_value":327602,"security_title":"Common Stock","importance":15.3276021},{"ts":"2026-05-14","kind":"sec.form144","reporter":"BOMBORA RISE FOUNDATION","title":"Family foundation of the CEO of EXEL.","shares":100000,"usd_value":5091190,"security_title":"Common","approx_sale_date":"2026-05-14","accession_number":"0001950047-26-004537","importance":41.018238},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Exelixis","title":"A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06952010","excerpt":"[\"Solid Tumor\",\"Advanced Solid Tumor\",\"Metastatic Solid Tumor\",\"Immune Sensitive Tumor\"]","importance":30},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"POSTE GEORGE","title":null,"shares":60000,"price_per_share":45.71,"usd_value":2742600,"security_title":"Common Stock","importance":37.7426},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"Freire Maria C","title":null,"shares":20634,"price_per_share":46,"usd_value":949164,"security_title":"Common Stock","importance":35.949164},{"ts":"2026-05-07","kind":"sec.insider.s","reporter":"Beckerle Mary C","title":null,"shares":7712,"price_per_share":48.45,"usd_value":373646,"security_title":"Common Stock","importance":35.3736464},{"ts":"2026-05-07","kind":"lobbying.filing","reporter":"W STRATEGIES, LLC","title":"Qs 2026 — RR","security_title":"EXELIXIS, INC.","usd_value":null,"accession_number":"8041ac3c-5f6d-44b1-8177-4efc7a6e29c0","excerpt":"PHA","importance":25},{"ts":"2026-05-07","kind":"sec.insider.m","reporter":"Freire Maria C","title":null,"shares":20634,"price_per_share":19.77,"usd_value":407934,"security_title":"Common Stock","importance":15.40793418},{"ts":"2026-05-07","kind":"sec.insider.m","reporter":"Beckerle Mary C","title":null,"shares":3856,"price_per_share":23.24,"usd_value":89613,"security_title":"Common Stock","importance":15.08961344},{"ts":"2026-05-06","kind":"sec.insider.g","reporter":"MORRISSEY MICHAEL","title":"President and CEO","shares":109676,"price_per_share":0,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Exelixis","title":"Study of XB010 in Subjects With Solid Tumors","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06545331","excerpt":"[\"Locally Advanced or Metastatic Solid Tumors\",\"Esophageal Squamous Cell Cancer\",\"Head and Neck Squamous Cell Cancer\",\"NSCLC (Non-small Cell Lung Cancer)\",\"Hormone-receptor-positive Breast Cancer\",\"Triple Negative Breast Cancer (TNBC)\"]","importance":30}]}